Financial statement review: First of all they were on

New Post Public Reply Private Reply Replies (1) Message Board
gopher broke
459
Financial statement review:

First of all they were on time and maybe even earlier than most expected.

Look at the last page of the July 31, 2019 financial statements, page 20 of 20, which compares the amounts due to Related Party (Steve Berman) for the first 9 months of this fiscal year.

Accrued but Unpaid Compensation - the difference is $180,000 or $20,000 per 9 month, meaning he has not paid himself one dime in salary. It shows up as a company expense on the Income Statement but nothing went out in cash to the CEO. If the company does well he will get paid down the road but during this growth stage, he is leaving it in the company to pay the bills.

Unreimbursed Business Expenses paid by the CEO has increased $300,300 during this fiscal year so he is paying for a lot of the company expenses out of his own wallet.

Accrued but unpaid sales commissions increased $540,461 during the 9 months. If you divide that number by 12.5%, you get $4,323,684, which just so happens to be the total sales for the first 9 months. Once again, he has not paid himself anything in commission. It is a debt of the company to be paid in the future when the company is in a position to pay it back.

5% loans made to the company increased $237,573 (including interest) during the 9 months which included $61,700 since April 30.

Not only is he not paying himself a salary or commissions but he has used over $300k of his own money for business expenses and has loaned the company an additional $237k.

Accounts Receivable 10/31/18 was $4,851,862 plus 9 months sales of $4,323,684 = $9,175,546. This represents the money owed the company if they did not collect any cash for their sales. Now subtract the A/R on 7/31/19 of $7,163,056 and you get the amount collected during the first 9 months, $2,012,490. People are buying the product and the company is making money.

Good luck

On4 Communications (ONCI) Stock Research Links

ONCI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 501

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 564

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 707

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 112

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 496

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading